Budaitis Brenna G, Firestein Zachary M, Yue Andrew C, White M Christina
Roger Adams Laboratory, Department of Chemistry, University of Illinois Urbana-Champaign, Urbana, Illinois 61801, United States.
J Am Chem Soc. 2025 Aug 28. doi: 10.1021/jacs.5c08883.
-alkyl arylamines are important structural motifs in pharmaceuticals, yet traditional alkylating methods rely on the nucleophilicity of the amine and make access to such compounds with valuable bioproperties challenging. While metal-mediated reactions may alleviate these limitations, they often encounter amine-metal interactions that can hinder catalysis or lead to deleterious pathways. Herein, we report a palladium(II) [Pd(II)]/sulfoxide-oxazoline(SOX)/phosphoric acid-mediated C(sp)H/N(sp) cross-coupling of 53 arylamine nucleophiles and 39 terminal olefins to furnish >80 diverse tertiary (3°) arylamines in excellent yields (average 82%) and selectivities (>20:1 /, >20:1 linear/branched). The reaction furnishes electron-deficient and sterically bulky arylamines as well as those housing alkyl/aryl halides, epoxides, carbonyls, epimerizable centers, carboxylic acids, and -triflyl/tosyl alkylamines, showcasing orthogonal scope to existing aminations. The generality of this reaction enables facile synthesis of six pharmaceuticals and derivatives (e.g., zafirlukast) and five late-stage drug fragment couplings (e.g., flutamide-duloxetine). Whereas spectroscopic studies identify a catalytically inactive bis(arylamine)·Pd(II) complex as the resting state, the reaction proceeds with high efficiencies (short reaction times, low catalyst loadings). Mechanistic studies reveal that the SOX ligand [(±)-MeO-SOX = MaSOX)] establishes a dynamic equilibrium with to generate the active catalyst. Phosphoric acids promote the reaction by affording a significant increase in the functionalization rate, rendering a lower energy allylic C-H cleavage as the rate-determining step. We anticipate that this reaction will find broad use in the discovery of complex and medicinally relevant -alkyl arylamines and that the mechanistic insights will be leveraged to improve efficiencies of other metal-catalyzed aminations.
烷基芳基胺是药物中重要的结构基序,但传统的烷基化方法依赖于胺的亲核性,使得获得具有重要生物特性的此类化合物具有挑战性。虽然金属介导的反应可能会缓解这些限制,但它们经常会遇到胺 - 金属相互作用,这可能会阻碍催化或导致有害途径。在此,我们报道了一种钯(II)[Pd(II)]/亚砜 - 恶唑啉(SOX)/磷酸介导的53种芳胺亲核试剂与39种末端烯烃的C(sp)H/N(sp)交叉偶联反应,以优异的产率(平均82%)和选择性(>20:1 /,>20:1线性/支化)提供了80多种不同的叔(3°)芳基胺。该反应提供了缺电子和空间位阻大的芳基胺,以及含有烷基/芳基卤化物、环氧化物、羰基、可差向异构化中心、羧酸和 - 三氟甲磺酰基/对甲苯磺酰基烷基胺的芳基胺,展示了与现有胺化反应正交的范围。该反应的通用性使得六种药物及其衍生物(如扎鲁司特)和五种后期药物片段偶联物(如氟他胺 - 度洛西汀)的合成变得容易。虽然光谱研究确定催化无活性的双(芳胺)·Pd(II)配合物为静止状态,但反应以高效率进行(反应时间短,催化剂负载量低)。机理研究表明,SOX配体[(±)-MeO - SOX = MaSOX]与 建立动态平衡以生成活性催化剂。磷酸通过显著提高官能化速率来促进反应,使较低能量的烯丙基C - H裂解成为速率决定步骤。我们预计该反应将在复杂的和与药物相关的 - 烷基芳基胺的发现中得到广泛应用,并且机理见解将被用于提高其他金属催化胺化反应的效率。